PHAXIAM Therapeutics SA (PHXM)

US29604W2070 - ADR

3.1  -0.02 (-0.64%)

After market: 3.1 0 (0%)

Full estimates are only available for subscribed users, you can see which data is available below.

Subscribed users also see more surprise data, now it is restricted to 4 quarters.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2020 2021 2022 2023 2024 2025 2026
Revenue
YoY % growth
3.718M
-42.45%		4.18M
12.43%		6.648M
59.04%
-100.00%
EBITDA
YoY % growth
-63.841M
-14.79%		-51.138M
19.90%		-22.528M
55.95%		-25.806M
-14.55%		-19.89M
22.92%		-20.4M
-2.56%		N/A
EBIT
YoY % growth
-68.832M
-14.14%		-56.515M
17.89%		-27.147M
51.96%		-26.418M
2.69%		-20.502M
22.39%		-21.012M
-2.49%		-21.322M
-1.48%
Operating Margin
-1,851.32%-1,352.03%-408.35%N/AN/AN/AN/A
EPS
YoY % growth
N/A
-5.11%		N/A
17.43%		N/A
51.41%		-1.62
77.73%		-0.95
41.29%		-0.73
22.94%		N/A

All data in EUR

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q4 / 23
EPS
Q2Q % growth		-0.14
86.11%
Revenue
Q2Q % growth		N/A
EBITDA
Q2Q % growth		N/A
EBIT
Q2Q % growth		N/A

All data in EUR

Recent Earnings VS Estimates Surprises (EUR)
PeriodReportedEstimateDifferenceSurprise
Q3 2023
Q2Q % growth
93.89%		-0.12%
Q2 2023
Q2Q % growth
80.53%		-0.12%
Q1 2023
Q2Q % growth
57.45%		-1.10%
Q4 2022
Q2Q % growth
62.50%		-0.99%
Q3 2022
Q2Q % growth
38.98%		-1.99%
Q2 2022
Q2Q % growth		 -0.59
81.72%		-3.092.4980.74%
Recent Revenue VS Estimates Surprises (EUR)
PeriodReportedEstimateDifferenceSurprise
Q3 2023
Q2Q % growth		 197K
-58.00%		%
Q2 2023
Q2Q % growth		 278K
-70.86%		%
Q1 2023
Q2Q % growth
-88.24%		299.88K%
Q4 2022
Q2Q % growth		 5.694M
272.16%		714K4.98M697.48%
Q3 2022
Q2Q % growth		 469K
-69.35%		%
Q2 2022
Q2Q % growth		 954K 2.55M-1.596M-62.59%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS0% 0% -15.5% -0.34%
RevenueN/A N/A N/A N/A